Andrew Saxon, MD

Recent Publications

High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder.
(2021 Jul 1)
JAMA Netw Open 4(7): e2117128
Herring AA, Vosooghi AA, Luftig J, Anderson ES, Zhao X, Dziura J, Hawk KF, McCormack RP, Saxon A, D'Onofrio G

Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems.
(2021 Jul 7)
Addict Sci Clin Pract 16(1): 46
Bagley SM, Chavez L, Braciszewski JM, Akolsile M, Boudreau DM, Lapham G, Campbell CI, Bart G, Yarborough BJH, Samet JH, Saxon AJ, Rossom RC, Binswanger IA, Murphy MT, Glass JE, Bradley KA, PROUD Collaborative.

Pain, cannabis use, and physical and mental health indicators among veterans and non-veterans: results from National Epidemiologic Survey on Alcohol and Related Conditions-III.
(2021 May 26)
Enkema MC, Hasin DS, Browne KC, Stohl M, Shmulewitz D, Fink DS, Olfson M, Martins SS, Bohnert KM, Sherman SE, Cerda M, Wall M, Aharonovich E, Keyhani S, Saxon AJ

Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
(2021 Jun 9)
Hser YI, Zhu Y, Fei Z, Mooney LJ, Evans EA, Kelleghan A, Matthews A, Yoo C, Saxon AJ

Prevalence of Medical Cannabis Use and Associated Health Conditions Documented in Electronic Health Records Among Primary Care Patients in Washington State.
(2021 May 3)
JAMA Netw Open 4(5): e219375
Matson TE, Carrell DS, Bobb JF, Cronkite DJ, Oliver MM, Luce C, Ghitza UE, Hsu CW, Campbell CI, Browne KC, Binswanger IA, Saxon AJ, Bradley KA, Lapham GT

Show complete publication list »
Edit Profile